Biomerica shares rise 22.36% premarket after CMS sets $300 Medicare payment rate for IBS test effective January 2026.

Biomerica (Nasdaq: BMRA) surged 22.36% in premarket trading following the announcement that the Centers for Medicare & Medicaid Services (CMS) has set a $300 national payment rate for its inFoods® IBS test under the Clinical Laboratory Fee Schedule. The pricing, effective January 1, 2026, provides clarity for Medicare reimbursement and establishes a foundation for negotiations with private insurers. The news also highlights the test’s potential to address a significant unmet medical need, as irritable bowel syndrome affects 10%–15% of U.S. adults. With Medicare covering 21% of U.S. healthcare expenditure and serving over 20% of IBS patients, the payment rate is expected to expand patient access and drive commercial growth. The milestone follows the American Medical Association’s approval of a dedicated CPT code for the test, further solidifying its market viability.